PK-DB: pharmacokinetics database for individualized and stratified computational modeling

A multitude of pharmacokinetics studies have been published. However, due to the lack of an open database, pharmacokinetics data, as well as the corresponding meta-information, have been difficult to access. We present PK-DB (https://pk-db.com), an open database for pharmacokinetics information from clinical trials including pre-clinical research. PK-DB provides curated information on (i) characteristics of studied patient cohorts and subjects (e.g. age, bodyweight, smoking status); (ii) applied interventions (e.g. dosing, substance, route of application); (iii) measured pharmacokinetic time-courses; (iv) pharmacokinetic parameters (e.g. clearance, half-life, area under the curve). Key features are the representation of experimental errors, the normalization of measurement units, annotation of information to biological ontologies, calculation of pharmacokinetic parameters from concentration-time profiles, a workflow for collaborative data curation, strong validation rules on the data, computational access via a REST API as well as human access via a web interface. PK-DB enables meta-analysis based on data from multiple studies and data integration with computational models. A special focus lies on meta-data relevant for individualized and stratified computational modeling with methods like physiologically based pharmacokinetic (PBPK), pharmacokinetic/pharmacodynamic (PK/DB), or population pharmacokinetic (pop PK) modeling.

[1]  Tudor Groza,et al.  The Monarch Initiative: an integrative data and analytic platform connecting phenotypes to genotypes across species , 2016, bioRxiv.

[2]  Erik Schultes,et al.  The FAIR Guiding Principles for scientific data management and stewardship , 2016, Scientific Data.

[3]  Gang Fu,et al.  Disease Ontology 2015 update: an expanded and updated database of human diseases for linking biomedical knowledge through disease data , 2014, Nucleic Acids Res..

[4]  A. Rostami-Hodjegan,et al.  Precision dosing in clinical medicine: present and future , 2018, Expert review of clinical pharmacology.

[5]  A. Staib,et al.  4-quinolones inhibit biotransformation of caffeine , 2004, European Journal of Clinical Pharmacology.

[6]  J. Ioannidis Reproducible pharmacokinetics , 2019, Journal of Pharmacokinetics and Pharmacodynamics.

[7]  K. Seng,et al.  Population pharmacokinetics of caffeine in healthy male adults using mixed‐effects models , 2009, Journal of clinical pharmacy and therapeutics.

[8]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling Methods , 2014, CPT: pharmacometrics & systems pharmacology.

[9]  Sherri de Coronado,et al.  NCI Thesaurus: A semantic model integrating cancer-related clinical and molecular information , 2007, J. Biomed. Informatics.

[10]  Tudor Groza,et al.  Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources , 2018, Nucleic Acids Res..

[11]  U. Fuhr,et al.  Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations. , 1989, The American journal of medicine.

[12]  The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects , 2013, European Journal of Clinical Pharmacology.

[13]  L Aarons,et al.  Population pharmacokinetics: theory and practice. , 1991, British journal of clinical pharmacology.

[14]  U. Hofmann,et al.  Evidence for morphine‐independent central nervous opioid effects after administration of codeine: Contribution of other codeine metabolites , 2006, Clinical pharmacology and therapeutics.

[15]  L. Benet,et al.  Pharmacokinetic parameters: which are necessary to define a drug substance? , 1984, European journal of respiratory diseases. Supplement.

[16]  D. Mays,et al.  Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics , 1986, Clinical pharmacology and therapeutics.

[17]  Johan Gabrielsson,et al.  Non-compartmental analysis. , 2012, Methods in molecular biology.

[18]  D. Moher,et al.  Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement , 2015, Clinical Pharmacokinetics.

[19]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development , 2012, CPT: pharmacometrics & systems pharmacology.

[20]  A. Staib,et al.  Decrease of caffeine elimination in man during co-administration of 4-quinolones. , 1987, The Journal of antimicrobial chemotherapy.

[21]  Leonid Hanin,et al.  Why statistical inference from clinical trials is likely to generate false and irreproducible results , 2017, BMC Medical Research Methodology.

[22]  Christoph Steinbeck,et al.  ChEBI in 2016: Improved services and an expanding collection of metabolites , 2015, Nucleic Acids Res..

[23]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods , 2013, CPT: pharmacometrics & systems pharmacology.

[24]  C. Tornøe,et al.  Reporting guidelines for population pharmacokinetic analyses , 2015, Journal of Pharmacokinetics and Pharmacodynamics.